Literature DB >> 22508158

Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.

Bo Shen1.   

Abstract

Restorative proctocolectomy with ileal pouch-anal anastomosis has become the procedure of choice for the majority of patients with ulcerative colitis who require surgical treatment. Pouchitis, the most common long-term complication of the procedure, involves a spectrum of disease processes with heterogeneous risk factors, clinical features, disease courses and prognoses. In addition, clinical symptoms of pouchitis are not specific and often overlap with those of other inflammatory and functional pouch disorders, such as Crohn's disease of the pouch and irritable pouch syndrome. Pouchoscopy and biopsy, along with laboratory and radiographic evaluations, are often required for accurate diagnosis in patients with symptoms indicative of pouchitis. Dysbiosis has been implicated as a triggering factor for pouchitis, and concurrent infection with pathogens, such as Clostridium difficile, might contribute to disease relapse and exacerbation. Antibiotic therapy is the main treatment modality. However, the management of antibiotic-dependent and antibiotic-refractory pouchitis remains challenging. Secondary causes of pouchitis, such as ischaemia, NSAID use, the presence of concurrent primary sclerosing cholangitis and other systemic immune-mediated disorders, should be evaluated and properly managed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22508158     DOI: 10.1038/nrgastro.2012.58

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  142 in total

1.  Reduced Paneth cell alpha-defensins in ileal Crohn's disease.

Authors:  Jan Wehkamp; Nita H Salzman; Edith Porter; Sabine Nuding; Michael Weichenthal; Robert E Petras; Bo Shen; Elke Schaeffeler; Matthias Schwab; Rose Linzmeier; Ryan W Feathers; Hiutung Chu; Heriberto Lima; Klaus Fellermann; Tomas Ganz; Eduard F Stange; Charles L Bevins
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

2.  Increased bacterial permeation in long-lasting ileoanal pouches.

Authors:  Anton J Kroesen; Patrick Leistenschneider; Katrin Lehmann; Christoph Ransco; Sonja Dullat; Michael Blaut; Joerg D Schulzke; Michael Fromm; Heinz J Buhr
Journal:  Inflamm Bowel Dis       Date:  2006-08       Impact factor: 5.325

3.  Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.

Authors:  P Gionchetti; F Rizzello; A Venturi; F Ugolini; M Rossi; P Brigidi; R Johansson; A Ferrieri; G Poggioli; M Campieri
Journal:  Aliment Pharmacol Ther       Date:  1999-06       Impact factor: 8.171

4.  TLR2 and TLR4 up-regulation and colonization of the ileal mucosa by Clostridiaceae spp. in chronic/relapsing pouchitis.

Authors:  Marco Scarpa; Alessia Grillo; Anna Pozza; Diego Faggian; Cesare Ruffolo; Melania Scarpa; Renata D'Incà; Mario Plebani; Giacomo Carlo Sturniolo; Ignazio Castagliuolo; Imerio Angriman
Journal:  J Surg Res       Date:  2011-05-05       Impact factor: 2.192

5.  Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor?

Authors:  Carmen B Meier; Refaat A Hegazi; James Aisenberg; Peter E Legnani; Naris Nilubol; Gena M Cobrin; Richard H Duerr; Stephen R Gorfine; Joel J Bauer; David B Sachar; Scott E Plevy
Journal:  Inflamm Bowel Dis       Date:  2005-11       Impact factor: 5.325

6.  Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors:  Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

7.  Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County.

Authors:  Karen Vanessa Winther; Tine Jess; Ebbe Langholz; Pia Munkholm; Vibeke Binder
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

8.  Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding.

Authors:  C P Kelly; C Pothoulakis; J Orellana; J T LaMont
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

9.  The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis.

Authors:  Bo Shen; Darrell S Pardi; Ana E Bennett; Elaine Queener; Patricia Kammer; Jefferey P Hammel; Caroline LaPlaca; M Scott Harris
Journal:  Am J Gastroenterol       Date:  2009-06       Impact factor: 10.864

10.  Cytokine production in pouchitis is similar to that in ulcerative colitis.

Authors:  R T Patel; I Bain; D Youngs; M R Keighley
Journal:  Dis Colon Rectum       Date:  1995-08       Impact factor: 4.585

View more
  30 in total

1.  Cytomegalovirus infection of the ileoanal pouch: clinical characteristics and outcomes.

Authors:  Jeffrey D McCurdy; Edward V Loftus; William J Tremaine; Thomas C Smyrk; David H Bruining; Darrell S Pardi; Laura E Raffals; John B Kisiel; Nayantara Coelho-Prabhu; Sunanda V Kane; William A Faubion; Konstantinos A Papadakis
Journal:  Inflamm Bowel Dis       Date:  2013-10       Impact factor: 5.325

2.  Fecal transplantation therapy for Clostridium difficile-associated pouchitis.

Authors:  Lisa N Patel; Jason Schairer; Bo Shen
Journal:  Int J Colorectal Dis       Date:  2013-10-17       Impact factor: 2.571

3.  Anxiety, depression, and inflammation after restorative proctocolectomy.

Authors:  Venkata Subhash Gorrepati; Sanjay Yadav; August Stuart; Walter Koltun; Evangelos Messaris; Emmanuelle D Williams; Matthew D Coates
Journal:  Int J Colorectal Dis       Date:  2018-06-29       Impact factor: 2.571

4.  Treatment strategy for preventing pouchitis as a postoperative complication of ulcerative colitis: the significance of the management of cuffitis.

Authors:  Takuzo Hashimoto; Michio Itabashi; Shinpei Ogawa; Tomoichiro Hirosawa; Yoshiko Bamba; Sanae Kaji; Mamiko Ubukata; Sayumi Nakao; Shingo Kameoka
Journal:  Surg Today       Date:  2014-07-15       Impact factor: 2.549

5.  Successful treatment of chronic refractory pouchitis with vedolizumab.

Authors:  Fazia Mir; Mohamad Hasan Yousef; Edward Kenneth Partyka; Veysel Tahan
Journal:  Int J Colorectal Dis       Date:  2017-07-11       Impact factor: 2.571

6.  Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.

Authors:  Bram Verstockt; Charlotte Claeys; Gert De Hertogh; Gert Van Assche; Albert Wolthuis; André D'Hoore; Séverine Vermeire; Marc Ferrante
Journal:  United European Gastroenterol J       Date:  2019-08-20       Impact factor: 4.623

Review 7.  Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?

Authors:  Georgina L Hold; Megan Smith; Charlie Grange; Euan Robert Watt; Emad M El-Omar; Indrani Mukhopadhya
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

8.  Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis.

Authors:  Maia Kayal; Michael Plietz; Marlana Radcliffe; Anam Rizvi; Clara Yzet; Emily Tixier; Robert P Hirten; Benjamin Cohen; Patricia Sylla; Sergey Khaitov; Alexander Greenstein; Jean-Frederic Colombel; Marla C Dubinsky; Ryan C Ungaro
Journal:  Aliment Pharmacol Ther       Date:  2019-10-03       Impact factor: 8.171

Review 9.  Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications.

Authors:  Ian M Carroll; Nitsan Maharshak
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

Review 10.  The gut microbiota in IBD.

Authors:  Chaysavanh Manichanh; Natalia Borruel; Francesc Casellas; Francisco Guarner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-08-21       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.